Your Directors submit their report for the half-year ended 31 December 2016.

DIRECTORS

The names and details of the Company's directors in office during the half-year and until the date of this report are as below. Directors were in office for this entire period unless otherwise stated.

Peter Terence Kempen
FCA, FAICD (Chairman)

Dr Sam Aaron Hupert
M.B.B.S. (Deputy Chairman and Chief Executive Officer)

Anthony Barry Hall
B.Sc.(Hons), M.Sc. (Executive Director and Technology Director)

Roderick Lewis John Lyle
LL.B., B.Com, LL.M (Lond), MBA (Melb) (Non-Executive Director)

Anthony James Glenning
B.Sc, B.Eng, M.EE (Non-Executive Director)

REVIEW AND RESULTS OF OPERATIONS

The Company reported a first half after tax profit of $4.80m, an increase of $1.86m (up 63.1%) compared to the same period last year. Revenue for the 6 month period of the Company increased from $14.28m to $15.20m, an increase of 6.4%.

The result from the underlying operations for the period was a profit of $4.08m compared to an underlying profit of $2.82m from the previous corresponding period, an increase of 44.7% (The underlying profit is made up of reported profit after-tax of $4.80m and subtracting the after-tax net currency gain of $0.72m (Dec 2015: $0.12m)).

During the period the Company continued to make strong inroads into the North America market winning an $18.0m contract with Mayo Clinic, one of the most recognised health systems in North America as well as globally. The Company made significant progress with its installations, with all key implementations being on or ahead of schedule.

The Company is looking to further build on its presence in North America and is actively pursuing key opportunities, both within the enterprise imaging/large teaching hospitals and private imaging centre markets.

The Company's European business performed in line with expectations. A capital sale of $1.5m in the previous corresponding period was not repeated in the current half.

The Company's Australian business improved as a result of increased adoption of the Visage RIS and Visage PACS products. Promedicus.net, the Company's e-health offering, continued to perform well throughout the period despite increasing competition.

The Company continued its significant investment in R&D, both in Australia as well as overseas.

The Company's cash reserves have increased by $3.17m for the 6 month period with cash reserves remaining high at $20.28m at the end of December 2016. The Company remains debt free.

The Board is of the view that there are sufficient cash reserves to fund the anticipated growth of the business from internal sources. As a result the Company has announced an unfranked interim dividend of 1.5c per share.

ROUNDING

The amounts contained in this report have been rounded to the nearest $1,000 (where rounding is applicable) under the option available to the company under ASIC Corporations (Rounding in Financial/Directors Reports) instrument 2016/191. The Company is an entity to which Legislative Instrument applies.

AUDITORS' INDEPENDENCE DECLARATION

In accordance with section 307C of the Corporations Act 2001, we have obtained a declaration of independence from our auditors Ernst & Young, a copy of which is attached.

Signed in accordance with a resolution of the directors.

P T Kempen
Chairman
Melbourne, 17 February 2017

Ernst & Young
8 Exhibition Street
Melbourne VIC 3000 Australia
GPO Box 67 Melbourne VIC 3001

Tel: +61 3 9288 8000
Fax: +61 3 8650 7777
ey.com/au

Auditor's Independence Declaration to the Directors of Pro Medicus Limited

As lead auditor for the review of Pro Medicus Limited for the half-year ended 31 December 2016, I declare to the best of my knowledge and belief, there have been:

a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

b) no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Pro Medicus Limited and the entities it controlled during the financial period.

Ernst & Young

Ernst & Young

Paul Gower

Paul Gower
Partner

17 February 2017

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE HALF-YEAR ENDED 31 DECEMBER 2016

	Notes	Consolidated **2016** **$'000**	2015 $'000
Continuing operations			
Revenue	2	**15,184**	14,260
Finance Revenue		**18**	25
Revenue		**15,202**	14,285
Cost of Sales		**(360)**	(482)
Gross Profit		**14,842**	13,803
Net Foreign Currency Gains	3a	**1,032**	171
Accounting and Secretarial Fees		**(370)**	(333)
Advertising and Public Relations		**(706)**	(714)
Depreciation & Amortisation	3b	**(2,081)**	(2,038)
Insurance		**(351)**	(287)
Legal Costs		**(156)**	(381)
Operating Lease Expenditure - minimum lease payments		**(255)**	(218)
Other Expense		**(190)**	(185)
Salaries and Employee Benefits Expense	3b	**(4,448)**	(4,868)
Travel and Accommodation		**(408)**	(470)
Profit before tax		**6,909**	4,480
Income tax expense	9	**(2,113)**	(1,539)
Profit for the period		**4,796**	2,941
Other comprehensive income			
Items that may be reclassified subsequently to profit and loss			
Foreign currency translation		**(281)**	183
Other comprehensive income for the period		**(281)**	183
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX		**4,515**	3,124
Earnings per share (cents per share)			
-basic for net profit for half-year		4.69¢	2.91¢
-diluted for net profit for the half-year		4.61¢	2.85¢

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2016

	Notes	Consolidated Dec 2016 $'000	Consolidated Jun 2016 $'000
ASSETS			
Current Assets			
Cash and cash equivalents	6	**20,278**	17,107
Trade and other receivables	7	**3,640**	4,771
Accrued revenue		**2,826**	2,258
Inventories		**66**	86
Prepayments		**594**	531
Total Current Assets		**27,404**	24,753
Non-Current Assets			
Deferred tax asset	9	**1,015**	757
Plant and equipment		**361**	382
Intangible assets	8	**14,274**	13,512
Prepayments		**368**	-
Total Non-Current Assets		**16,018**	14,651
TOTAL ASSETS		**43,422**	39,404
LIABILITIES			
Current Liabilities			
Trade and other payables	10	**2,988**	2,994
Income tax payable		**2,116**	2,747
Provisions		**1,743**	1,826
Total Current Liabilities		**6,847**	7,567
Non-Current Liabilities			
Deferred tax liabilities	9	**5,249**	4,386
Provisions		**78**	66
Total Non-Current Liabilities		**5,327**	4,452
TOTAL LIABILITIES		**12,174**	12,019
NET ASSETS		**31,248**	27,385
EQUITY			
Contributed Equity		**1,937**	1,302
Treasury Share Reserve		**(73)**	-
Share Based Payment Reserve		**1,425**	1,104
Foreign Currency Translation Reserve		**(164)**	117
Retained Earnings		**28,123**	24,862
TOTAL EQUITY		**31,248**	27,385

pro medicus
OUR SUPPORT. YOUR SUCCESS.

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE HALF-YEAR ENDED 31 DECEMBER 2016

	Consolidated					
	Issued Capital	Treasury Share Reserve	Share Based Payment Reserve	Foreign Currency Translation Reserve	Retained Earnings	Total Equity
	$'000	$'000	$'000	$'000	$'000	$'000
At 1 July 2016	1,302	-	1,104	117	24,862	27,385
Profit for the period	-	-	-	-	4,796	4,796
Other comprehensive income	-	-	-	(281)	-	(281)
Total comprehensive income for the period	-	-	-	(281)	4,796	4,515
Transactions with owners in their capacity as owners						
Share based payment	-	-	321	-	-	321
Exercise of share options	635	-	-	-	-	635
Share buy-back	-	(73)	-	-	-	(73)
Dividends	-	-	-	-	(1,535)	(1,535)
At 31 December 2016	**1,937**	**(73)**	**1,425**	**(164)**	**28,123**	**31,248**

	Issued Capital	Treasury Share Reserve	Share Based Payment Reserve	Foreign Currency Translation Reserve	Retained Earnings	Total Equity
	$'000	$'000	$'000	$'000	$'000	$'000
At 1 July 2015	327	-	666	(81)	21,026	21,938
Profit for the period	-	-	-	-	2,941	2,941
Other comprehensive income	-	-	-	183	-	183
Total comprehensive income for the period	-	-	-	183	2,941	3,124
Transactions with owners in their capacity as owners						
Share based payment	-	-	168	-	-	168
Exercise of share options	925	-	-	-	-	925
Dividends	-	-	-	-	(1,007)	(1,007)
At 31 December 2015	1,252	-	834	102	22,960	25,148

INTERIM CONSOLIDATED STATEMENT OF CASH FLOW

FOR THE HALF-YEAR ENDED 31 DECEMBER 2016

	Notes	Consolidated 2016 $'000	2015 $'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		**15,749**	12,483
Payments to suppliers and employees		**(7,412)**	(7,001)
Income tax (paid)/refund		**(2,140)**	250
NET CASH FLOWS FROM OPERATING ACTIVITIES		**6,197**	5,732
CASH FLOWS USED IN INVESTING ACTIVITIES			
Capitalised development costs	8	**(2,753)**	(2,672)
Interest received		**18**	25
Purchase of property, plant and equipment		**(69)**	(103)
NET CASH FLOWS USED IN INVESTING ACTIVITIES		**(2,804)**	(2,750)
CASH FLOWS USED IN FINANCING ACTIVITIES			
Payment of dividends on ordinary shares	4b	**(1,535)**	(1,007)
Payment for share buy-back		**(73)**	-
Proceeds from issuing shares		**635**	925
NET CASH FLOWS USED IN FINANCING ACTIVITIES		**(973)**	(82)
Net increase in cash and cash equivalents		**2,420**	2,900
Net foreign exchange differences		**751**	355
Cash and cash equivalents at beginning of period		**17,107**	12,935
CASH AND CASH EQUIVALENTS AT END OF PERIOD	6	**20,278**	16,190

Notes to the Financial Statements
FOR THE HALF-YEAR ENDED 31 DECEMBER 2016

1. Corporate Information

The interim consolidated financial statements of the Group for the half-year ended 31 December 2016 were authorised for issue in accordance with a resolution of directors on 17 February 2017.

Pro Medicus Limited is a for profit company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange.

The nature of the operations and principal activities of the Company are described in note 2.

BASIS OF PREPARATION AND ACCOUNTING POLICIES

(a) Basis of Preparation

The interim consolidated financial statements for the half-year ended 31 December 2016 have been prepared in accordance with AASB 134 *Interim Financial Reporting.*

The interim consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements for the year ended 30 June 2016, together with any public announcements made by the Company during the half-year ended 31 December 2016.

(b) Significant accounting policies

Apart from the changes in accounting policy noted below, accounting policies and methods of computation are the same as those adopted in the most recent annual financial statements for the year ended 30 June 2016.

(i) Treasury shares

Own equity instruments that are reacquired (treasury shares) are recognised at cost and deducted from equity. No gain or loss is recognised in profit or loss on the purchase, sale, issue or cancellation of the Group's own equity instruments.

(c) Changes in accounting policy

The accounting policies adopted in the preparation of the interim financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2016.

The Group has adopted the applicable changes in accounting standards for the half-year ended 31 December 2016 and are of the view that the adoption of the standards did not have an affect on the financial position or the performance of the Group. In addition, the Group has elected not to adopt any new standards or amendments issued but not yet effective.

Notes to the Financial Statements
FOR THE HALF-YEAR ENDED 31 DECEMBER 2016

2. SEGMENT INFORMATION

The Group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team (the chief operating decision makers) in assessing performance and in determining the allocation of resources.

The operating segments are identified by management based on country of origin. Discrete financial information is reported to the executive management team on at least a monthly basis.

Impairment is not monitored at a segment level. Impairment is monitored at a product level.

Types of products and services
The Group produces integrated software applications for the health care industry. In addition the Group provides services in the form of installation and support.

Accounting policies and inter-segment transactions
The accounting policies used by the Group in reporting segments internally are the same as those used in preparing the financial statements in prior periods.

Inter-entity sales
Inter-entity sales are recognised based on an internally set transfer price. The price aims to reflect what the business operation could achieve if they sold their output and services to external parties at arm's length.

Operating Segments

Half-year ended 31 Dec 2016	Australia		Europe		North America		Total Operations	
	Dec 2016 $'000	Dec 2015 $'000	**Dec 2016 $'000**	Dec 2015 $'000	**Dec 2016 $'000**	Dec 2015 $'000	**Dec 2016 $'000**	Dec 2015 $'000
Revenue								
Sales to external customers - software	**4,370**	3,462	**819**	2,161	**9,594**	8,081	**14,783**	13,704
Sales to external customers - hardware	**401**	-	**-**	556	**-**	-	**401**	556
Inter-segment sales	**5,674**	5,091	**2,350**	2,306	**-**	-	**8,024**	7,397
Total segment revenue	**10,445**	8,553	**3,169**	5,023	**9,594**	8,081	**23,208**	21,657
Inter-segment elimination							**(8,024)**	(7,397)
Total consolidation revenue							**15,184**	14,260
Results								
Segment Result	**6,035**	3,256	**607**	1,026	**249**	173	**6,891**	4,455
Interest Revenue							**18**	25
Non segment expenses								
Income Tax (Expense)/Benefit							**(2,113)**	(1,539)
Net Profit/(Loss)							**4,796**	2,941

	Dec 2016 $'000	June 2016 $'000	**Dec 2016 $'000**	June 2016 $'000	**Dec 2016 $'000**	June 2016 $'000	**Dec 2016 $'000**	June 2016 $'000
Assets								
Segment Assets	**48,181**	46,697	**22,989**	23,519	**21,442**	16,840	**92,612**	87,056
Inter-segment elimination							**(49,190)**	(47,652)
Total Assets							**43,422**	39,404
Liabilities								
Segment Liabilities	**35,504**	37,665	**1,774**	2,275	**20,637**	16,095	**57,915**	56,035
Inter-segment elimination							**(45,741)**	(44,016)
Total Liabilities							**12,174**	12,019

Product information

	Consolidated	
Revenue from External customers	**Dec 2016 $'000**	Dec 2015 $'000
Radiology Information Systems (RIS)	**3,522**	3,108
Picture Archiving Communications Systems (Visage 7/PACS)	**11,239**	10,580
Hardware income	**401**	556
Other income	**22**	16
	15,184	14,260

Notes to the Financial Statements
FOR THE HALF-YEAR ENDED 31 DECEMBER 2016

3. EXPENSES

	Consolidated	
	Dec 2016	Dec 2015
	$'000	$'000
(a) Net Foreign Currency Gains/(Loss)		
Currency Gains	**2,087**	459
Currency (Loss)	**(1,055)**	(288)
	1,032	171
(b) Expenses		
Depreciation and Amortisation		
Property Improvements	**1**	1
Motor Vehicles	**4**	4
Office Equipment	**74**	70
Furniture and Fittings	**11**	5
Amortisation on computer software	**1**	1
Amortisation on capitalised development costs	**1,990**	1,957
Total Depreciation and Amortisation Expenses	**2,081**	2,038
Salaries and Employee Benefits Expense		
Wages & Salaries **	**3,658**	4,036
Long service leave provision	**25**	208
Share-based payment ***	**321**	168
Defined contribution plan expense	**444**	456
	4,448	4,868

** - The Group's total Wages & Salaries incurred was $5,826,000 (2015:$6,203,000) of which $2,168,000 (2015:$2,166,000) of these costs have been capitalised.

*** - On 19 October 2016 90,000 performance rights were granted under the current long term incentive plan in relation to the 2016-17 financial year. The performance rights vest over 4 years from grant date on completion of service. The fair value of the 90,000 performance rights at grant date was $439,326 ($4.88 per performance right), a portion of which has been expensed for the half-year ended 31 December 2016.

A further 180,492 performance rights were also granted on 19 October 2016 under a new long term incentive plan in relation to the financial years ending 2017, 2018 and 2019. The performance rights vest over 4 years from grant date on completion of service. The fair value of the performance rights at grant date was $3.61 per performance right. The amount of share-based payment expense for the half-year ended 31 December 2016 takes into consideration the probability of certain performance conditions vesting.

Notes to the Financial Statements
FOR THE HALF-YEAR ENDED 31 DECEMBER 2016

4. DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES

	Consolidated	
	Dec 2016 $'000	Dec 2015 $'000
(a) Dividends proposed and recognised as a liability		
Franked dividend	**-**	-
(b) Dividends paid during the half-year		
Franked dividend	**-**	-
Unfranked dividend	**1,535**	1,007
(c) Dividends proposed and not recognised as a liability		
Interim Unfranked dividend	**1,540**	1,526
Dividends per share (cents per share)		
-Franked dividends paid per share (cents per share)	**Nil**	Nil
-interim dividend per share	**1.50¢**	1.50¢

5. EVENTS AFTER THE BALANCE SHEET DATE
On 17 February 2017, the directors of Pro Medicus Limited declared an interim dividend of 1.5 cents per share.
The total amount of the dividend is $1,539,908 which represents an unfranked dividend of a total of 1.5 cents per share.
The dividend has not been provided for in the 31 December 2016 financial statements.

6. CASH AND CASH EQUIVALENTS

Reconciliation of Cash
For the purposes of the Statement of Cash Flow, cash and cash equivalents comprise the following at 31 December:

	Dec 2016 $'000	Jun 2016 $'000
Cash at bank and in hand	**20,278**	15,577
Short term deposits	**-**	1,530
	20,278	17,107

7. TRADE AND OTHER RECEIVABLES

	Dec 2016 $'000	Jun 2016 $'000
Trade receivables	**3,442**	3,533
	3,442	3,533
Research & development right to receive	**-**	989
Other receivables	**198**	249
	3,640	4,771

8. INTANGIBLE ASSETS

			Consolidated	
	Intellectual Property $'000	Development Costs $'000	Software Licenses $'000	Total $'000
Half-year ended 31 December 2016				
At 1 July 2016 net of accumulated amortisation and impairment	-	13,510	2	13,512
Additions - internal development	-	2,753	-	2,753
Amortisation charge for the period	-	(1,990)	(1)	(1,991)
At 31 December 2016 net of accumulated amortisation and impairment	-	14,273	1	14,274
At 31 December 2016				
Cost	1,848	35,408	290	37,546
Accumulated amortisation	(1,848)	(21,135)	(289)	(23,272)
Net carrying amount	-	14,273	1	14,274
Year ended 30 June 2016				
At 1 July 2015 net of accumulated amortisation and impairment	-	11,549	3	11,552
Additions - internal development	-	5,607	-	5,607
Amortisation charge for the year	-	(3,646)	(1)	(3,647)
At 30 June 2016 net of accumulated amortisation and impairment	-	13,510	2	13,512
At 30 June 2016				
Cost	1,848	32,655	296	34,799
Accumulated amortisation	(1,848)	(19,145)	(294)	(21,287)
Net carrying amount	-	13,510	2	13,512

In accordance with the Group's accounting policies and process, the Group evaluated each cash generating unit ('CGU') at 31 December 2016, to determine whether they were any indications of impairment. Where an indicator of impairment exists a formal estimate of the recoverable amount is performed.

After consideration of potential indicators which could impact the valuation of the CGU's at 31 December, the Group concluded there are no impairment indicators for the Group's CGU's as at 31 December 2016.

Impact of judgements and estimates on valuation outcomes
It should be noted that significant judgement and assumptions are required in making estimates of an asset's recoverable amount. This is particularly so in the assessment of long life assets. The projected cash flows used in the recoverable amount valuation are subject to variability in key assumptions, including, but not limited to revenue forecasts. A change in the revenue forecasts used in the estimates could result in a change in an asset's recoverable amount as outlined in the 30 June 2016 annual financial report.

9. INCOME TAX

The Group calculates the period income tax expense using the tax rate that would be applicable to expected total annual earnings, i.e., the estimated average annual effective income tax rate applied to the pre-tax income of the interim period.

The major components of income tax expense in the interim consolidated income statements are:

Income taxes	Dec 2016 $'000	Dec 2015 $'000
Current income tax expense	**(1,677)**	(726)
Prior year adjustment	**169**	(87)
Deferred income tax (expense)/benefit related to origination and reversal of deferred taxes	**(605)**	(726)
Income tax expense	**(2,113)**	(1,539)
Income tax recognised in other comprehensive income	**-**	-
Total income tax expense	**(2,113)**	(1,539)

	Interim Consolidated Statement of Financial Position		Interim Consolidated Statement of Comprehensive Income	
Deferred tax liabilities	**Dec 2016 $'000**	Jun 2016 $'000	**Dec 2016 $'000**	Dec 2015 $'000
Foreign currency exchange gain	**1,250**	886	**(364)**	(46)
Capitalised development expenses	**3,923**	3,500	**(423)**	(726)
Depreciation expenses	**74**	-	**(74)**	-
Other	**2**	-	**(2)**	(3)
	5,249	4,386	**(863)**	(775)
Deferred tax assets				
Employment entitlements	**666**	411	**255**	104
Intellectual property expenses	**317**	326	**(9)**	(9)
Tax losses	**-**	-	**-**	(53)
Audit fee accrual	**30**	16	**14**	4
Other	**2**	4	**(2)**	3
	1,015	757	**258**	49
Deferred tax expense			**(605)**	(726)

10. TRADE AND OTHER PAYABLES

Current	Dec 2016 $'000	Jun 2016 $'000
Trade payables	**328**	676
Other payables and accruals	**2,009**	1,383
	2,337	2,059
Deferred Income	**651**	935
	2,988	2,994

Directors' Declaration

In accordance with a resolution of the directors of Pro Medicus Limited, I state that:

In the opinion of the directors:

(a) The Financial Statements and notes of the consolidated entity are in accordance with the *Corporations Act 2001* , including:

(i) giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the half-year ended on that date; and

(ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Regulations 2001

(b) There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

On behalf of the Board

P T Kempen
Chairman
Melbourne, 17 February 2017

Ernst & Young
8 Exhibition Street
Melbourne VIC 3000 Australia
GPO Box 67 Melbourne VIC 3001

Tel: +61 3 9288 8000
Fax: +61 3 8650 7777
ey.com/au

To the members of Pro Medicus Limited

Report on the 31 December 2016 Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Pro Medicus Limited, which comprises the statement of financial position as at 31 December 2016, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the half-year end or from time to time during the half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal controls as the directors determine are necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001.* As the auditor of Pro Medicus Limited and the entities it controlled during the half-year, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We have given to the directors of the company a written Auditor's Independence Declaration, a copy of which is included in the Directors' Report.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Pro Medicus Limited is not in accordance with the *Corporations Act 2001*, including:

a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the half-year ended on that date; and

b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Ernst & Young

Paul Gower
Partner
Melbourne

17 February 2017